title: [Serum CXCL-10 level in chronic hepatitis C patients with cryoglobulinemia and its influence on antiviral therapy].
abstract: Objective:To investigate the serum CXCL-10 level in chronic hepatitis C (CHC) patients with cryoglobulinemia and its influence on the effect of antiviral therapy.Methods:A total of 50 CHC patients were enrolled in the study. Cryoprecipitation was used to determine the nature of cryoglobulins in serum before treatment, and ELISA was used to measure the serum CXCL-10 level. The hepatitis C virus (HCV) genotype was detected, and serum HCV RNA level was measured at baseline, 4, 12, and 24 weeks of treatment, the end of treatment, and 24 weeks after treatment..Results:Compared with the cryoglobulin-negative patients, the cryoglobulin-positive patients had significantly higher baseline levels of HCV RNA [(6.28±0.79) log10 copies/ml vs (5.48±1.20) log10 copies/ml,P= 0.009] and CXCL-10 (541.67±224.07 pg/ml vs 394.39±179.71 pg/ml,P= 0.015). After the treatment with pegylated interferon-α-2a and ribavirin, the cryoglobulin-positive patients had a significantly lower proportion of individuals who achieved rapid virological response compared with the cryoglobulin-negative patients (33.3% vs 82.6%,P< 0.001). The cryoglobulin-positive patients had a significantly lower rate of sustained virologic response than the cryoglobulin-negative patients (33.3% vs 78.3%,P= 0.001).Conclusion:The patients with cryoglobulinemia have higher serum levels of HCV RNA and CXCL-10 and poor outcomes compared with those without cryoglobulinemia.
authors.affiliation: Department of Gastroenterology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province 030001, China.
authors.forename: X H
authors.initials: XH
authors.lastname: Fan
authors.affiliation: Department of Gastroenterology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province 030001, China.
authors.forename: Z H
authors.initials: ZH
authors.lastname: Deng
authors.affiliation: Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
authors.forename: X Y
authors.initials: XY
authors.lastname: Xu
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016022:Case-Control Studies; D054357:Chemokine CXCL10 / Q000097:blood*; D003449:Cryoglobulinemia; D003450:Cryoglobulins / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; C114753:CXCL10 protein, human; D054357:Chemokine CXCL10; D003450:Cryoglobulins; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a